Ovarian cancer often goes undetected until it spreads to other areas. In its late stages, it's harder to treat. Now there's an unconventional treatment being used to get rid of it. When her stomach ...

In over 400 women at first epithelial ovarian cancer recurrence, those who received HIPEC had a median OS of 54.3 months compared with 45.8 months for those who did not (HR 0.73, 95% CI 0.56-0.96, P=0 ...

SCS combined with HIPEC may improve overall survival in PSROC patients compared to SCS alone, with a statistically significant benefit observed. The risk of severe complications, including anemia and ...

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer. Among patients with platinum-sensitive peritoneal ...

COIMBATORE: The Coimbatore Medical College Hospital (CMCH) is set to introduce a new medical procedure, Hyperthermic ...

Median progression-free survival (PFS) improved from 23 months with surgery alone to 25 months with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC), a nonsignificant difference. Post ...

DETAILS ON THE HIPEC PROCEDURE. PAM PHILLIPS IS GRATEFUL FOR EVERY MINUTE IN 2020 FOR 11 NEWS FIRST CAUGHT UP WITH HER NINE YEARS AGO WHEN SHE WAS A NEW CANCER SURVIVOR IN 2009, SHE WAS DIAGNOSED WITH ...

Ceralasertib (cerala) + olaparib (ola) in patients (pts) with homologous recombination repair (HRR)-deficient platinum-sensitive relapsed ovarian cancer (OC) after progression on prior PARP inhibitor ...

Please provide your email address to receive an email when new articles are posted on . In this video, Robert DeBernardo, MD, discusses his research on hyperthermic intraperitoneal chemotherapy among ...

KMC Attavar has achieved a medical milestone. A specialized team successfully conducted a complex surgery for a rare abdominal cancer. This advanced t ...